Exactmer has exclusive rights to the patented Nanostar Sieving technology, which allows synthesis of exact polymers in liquid phase.
There is increasing interest in using biopolymers such as oligonucleotides to develop new therapies for a wide range of currently untreatable diseases. These polymers are mostly prepared by solid-state synthesis, resulting in very poor scaling capabilities, low final purity and high prices. This means that the promising development of new therapies is currently limited by the high cost of manufacture - we believe Exactmer can help to solve this problem.
The technology comprises a coupling reaction in which multiple growing polymer chains are attached to a central hub molecule to create a “nanostar” with enhanced molecular size. Each monomer is added to the polymer chains iteratively, until the exact polymer sequence is achieved. At each iteration the growing polymer is effectively purified by removing the reaction debris via purpose-designed nanomembrane filtration, until the final polymer is produced.
We are planning to operate our technology in a GMP (Good Manufacturing Practice) facility by the end of 2023.